Nektar Therapeutics (NKTR)
| Market Cap | 1.94B +1,414.2% |
| Revenue (ttm) | 55.63M -36.2% |
| Net Income | -158.10M |
| EPS | -8.09 |
| Shares Out | 33.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,033,573 |
| Open | 59.24 |
| Previous Close | 59.31 |
| Day's Range | 56.81 - 60.00 |
| 52-Week Range | 7.99 - 109.00 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 153.25 (+167.36%) |
| Earnings Date | May 7, 2026 |
About NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col... [Read more]
Financial Performance
In 2025, Nektar Therapeutics's revenue was $55.23 million, a decrease of -43.89% compared to the previous year's $98.43 million. Losses were -$164.08 million, 37.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price target is $153.25, which is an increase of 167.36% from the latest price.
News
Nektar Therapeutics Transcript: AGM 2026
The meeting approved all four proposals, including director election and plan amendments. Immunology pipeline advances with REZPEG moving to phase III, and strong cash reserves support future studies. Collaboration on REZPEG is possible, but licensing is not planned.
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted...
Nektar Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Rezpegaldesleukin, a Treg agonist, is advancing through global phase III trials for atopic dermatitis, with robust design and strategic differentiation for biologic-naive and experienced populations. Additional studies in alopecia and type 1 diabetes are planned, with broad potential across immune-mediated diseases.
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conf...
Nektar price target lowered to $80 from $95 at Wedbush
Wedbush analyst Martin Fan lowered the firm’s price target on Nektar (NKTR) to $80 from $95 and keeps a Neutral rating on the shares. The firm notes the company reported…
Nektar price target raised to $192 from $105 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Nektar (NKTR) to $192 from $105 and keeps an Overweight rating on the shares. The firm notes the company…
Nektar Therapeutics Earnings Call Transcript: Q1 2026
REZPEG showed strong efficacy and durability in phase IIb studies for atopic dermatitis and alopecia areata, supporting phase III trials in both. Financials remain robust with over $1 billion in cash, funding operations through key milestones.
Nektar Therapeutics Earnings release: Q1 2026
Nektar Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Nektar Therapeutics Quarterly report: Q1 2026
Nektar Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)
Reports Q1 revenue $10.86M, consensus $10.69M. “2026 is shaping up to be a defining year for Nektar (NKTR) and for our lead biologic candidate rezpegaldesleukin,” said Howard Robin, President and…
Nektar Therapeutics Reports First Quarter 2026 Financial Results
SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities...
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based finan...
Nektar Therapeutics Proxy statement: Proxy filing
Nektar Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Nektar Therapeutics Proxy statement: Proxy filing
Nektar Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closi...
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap...
Nektar price target raised to $95 from $70 at Wedbush
Wedbush raised the firm’s price target on Nektar (NKTR) to $95 from $70 and keeps a Neutral rating on the shares. The firm notes Nektar reported deepening responses in 52-week…
Nektar price target raised to $151 from $123 at Citi
Citi raised the firm’s price target on Nektar (NKTR) to $151 from $123 and keeps a Buy rating on the shares. The firm cites the positive alopecia areata data for…
Nektar announces $250M common stock offering
Nektar (NKTR) Therapeutics announced that it has commenced an underwritten public offering of $250M of its shares of its common stock and, in lieu of common stock to certain investors,…
Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap...
This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness.
Nektar Therapeutics releases positive results from its trial for the treatment of alopecia areata.
Nektar price target raised to $185 from $165 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nektar (NKTR) to $185 from $165 and keeps a Buy rating on the shares after the company reported “strong” 16-week treatment extension…
Nektar Therapeutics Transcript: Study update
The 52-week REZOLVE-AA phase II-B extension showed rezpeg led to significant, durable hair regrowth in severe alopecia areata, with a favorable safety profile and no new safety signals. Experts expect rezpeg to become a first-line therapy, shifting treatment away from JAK inhibitors.